{"id":"omecamtiv-mecarbil-om","safety":{"commonSideEffects":[{"rate":null,"effect":"Ventricular arrhythmias"},{"rate":null,"effect":"Increased troponin levels"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1800955","moleculeType":"Small molecule","molecularWeight":"401.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug binds to cardiac myosin and increases the probability that myosin heads will enter the force-generating state, thereby enhancing cardiac contractility without increasing heart rate or oxygen consumption proportionally. This mechanism is distinct from traditional inotropes and aims to improve cardiac output in heart failure patients by making the existing heart muscle work more efficiently.","oneSentence":"Omecamtiv mecarbil is a cardiac myosin activator that directly enhances the force of heart muscle contraction by increasing the number of myosin heads that generate force during systole.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:11.756Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Heart failure with reduced ejection fraction (HFrEF)"},{"name":"Acute heart failure"}]},"trialDetails":[{"nctId":"NCT06736574","phase":"PHASE3","title":"Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction","status":"RECRUITING","sponsor":"Cytokinetics","startDate":"2024-12-19","conditions":"Heart Failure, Heart Failure With Reduced Ejection Fraction","enrollment":1800},{"nctId":"NCT04175808","phase":"PHASE1","title":"Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults","status":"COMPLETED","sponsor":"Cytokinetics","startDate":"2019-11-14","conditions":"QT Intervals Changes, QTc Intervals Changes","enrollment":70},{"nctId":"NCT02929329","phase":"PHASE3","title":"Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction","status":"COMPLETED","sponsor":"Cytokinetics","startDate":"2017-01-06","conditions":"Heart Failure","enrollment":8256},{"nctId":"NCT01786512","phase":"PHASE2","title":"COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure","status":"COMPLETED","sponsor":"Cytokinetics","startDate":"2013-02-26","conditions":"Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction, Chronic Heart Failure","enrollment":544},{"nctId":"NCT04464525","phase":"PHASE3","title":"Omecamtiv Mecarbil Post-trial Access Study","status":"WITHDRAWN","sponsor":"Cytokinetics","startDate":"2020-12-18","conditions":"Chronic Heart Failure With Reduced Ejection Fraction","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AMG 423"],"phase":"phase_3","status":"active","brandName":"Omecamtiv Mecarbil (OM)","genericName":"Omecamtiv Mecarbil (OM)","companyName":"Cytokinetics","companyId":"cytokinetics","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Omecamtiv mecarbil is a cardiac myosin activator that directly enhances the force of heart muscle contraction by increasing the number of myosin heads that generate force during systole. Used for Heart failure with reduced ejection fraction (HFrEF), Acute heart failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}